In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
The in vitro activities of LY333328 were compared with those of vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. MICs and MBCs were determined by a microtiter dilution protocol. LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Its potency was comparable or superior to those of other antibiotics tested against methicillin-resistant staphylococci.
Schwalbe
R S
RS
Department of Pathology, University of Maryland School of Medicine, Baltimore, USA.
McIntosh
A C
AC
Qaiyumi
S
S
Johnson
J A
JA
Johnson
R J
RJ
Furness
K M
KM
Holloway
W J
WJ
Steele-Moore
L
L
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016983:Enterococcus / Q000187:drug effects*; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects*; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology / Q000031:analogs & derivatives; D014769:Virginiamycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D017334:Teicoplanin; D014640:Vancomycin; C100708:oritavancin